Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

939908

	registered interest
	date	12/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Olanzapine and Quetiapine
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with which manufacturers of (a) olanzapine and (b) quetiapine his Department has had discussions since 2017.
	tabling member constituency	Twickenham
	tabling member printed	Sir Vince Cable
	uin	163503
	answer	answer is ministerial correction date of answer 20/07/2018 answer text <p>Departmental officials are aware that there were some short term supply issues which affected the availability of olanzapine and quetiapine tablets in May/June 2017.</p><p> </p><p>A major generic supplier of olanzapine tablets experienced some short term manufacturing issues which consequently meant other suppliers experienced an increase in demand at short notice, which they could not readily meet. However, the manufacturing issues were resolved quickly and the overall supply of olanzapine tablets improved within a few weeks.</p><p> </p><p>In terms of quetiapine supply issues, this was caused by a major generic supplier, with large market shares of quetiapine tablets, discontinuing this product range without notifying the Department. This led to significant market disruption as other suppliers experienced a large increase in demand at short notice. However, suppliers were able to bring in additional supplies to cope with the extra demand and supplies improved by July 2017.</p><p> </p><p>During this period, Departmental officials were in regular contact with all United Kingdom licensed suppliers of both quetiapine and olanzapine and worked closely with them to discuss their supply position and to ensure sufficient suppliers remained available to meet UK requirements.</p><p> </p><p>We are not aware of any current supply issues affecting olanzapine and quetiapine and several suppliers have confirmed that supplies are readily available.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 162968 162969 question first answered 20/07/2018 09:38:48 answering member 4067 label Biography information for Steve Brine
	tabling member	207 label Biography information for Sir Vince Cable

938699

	registered interest
	date	11/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Olanzapine and Quetiapine
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help ensure the supply of (a) olanzapine and (b) quetiapine meets demand for those drugs.
	tabling member constituency	Twickenham
	tabling member printed	Sir Vince Cable
	uin	162968
	answer	answer is ministerial correction date of answer 20/07/2018 answer text <p>Departmental officials are aware that there were some short term supply issues which affected the availability of olanzapine and quetiapine tablets in May/June 2017.</p><p> </p><p>A major generic supplier of olanzapine tablets experienced some short term manufacturing issues which consequently meant other suppliers experienced an increase in demand at short notice, which they could not readily meet. However, the manufacturing issues were resolved quickly and the overall supply of olanzapine tablets improved within a few weeks.</p><p> </p><p>In terms of quetiapine supply issues, this was caused by a major generic supplier, with large market shares of quetiapine tablets, discontinuing this product range without notifying the Department. This led to significant market disruption as other suppliers experienced a large increase in demand at short notice. However, suppliers were able to bring in additional supplies to cope with the extra demand and supplies improved by July 2017.</p><p> </p><p>During this period, Departmental officials were in regular contact with all United Kingdom licensed suppliers of both quetiapine and olanzapine and worked closely with them to discuss their supply position and to ensure sufficient suppliers remained available to meet UK requirements.</p><p> </p><p>We are not aware of any current supply issues affecting olanzapine and quetiapine and several suppliers have confirmed that supplies are readily available.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 162969 163503 question first answered 20/07/2018 09:38:48 answering member 4067 label Biography information for Steve Brine
	tabling member	207 label Biography information for Sir Vince Cable

939907

	registered interest
	date	12/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Olanzapine and Quetiapine
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what representations his Department has received on the extent to which (a) olanzapine and (b) quetiapine have not been prescribed on account of limitations on the availability of those drugs over the last three years; and what information his Department holds on the number of people who were prescribed (a) olanzapine and (b) quetiapine but were not able to receive those drugs due to limited availability in (i) 2016, (ii) 2017 and (iii) 2018 to date.
	tabling member constituency	Twickenham
	tabling member printed	Sir Vince Cable
	uin	163502
	answer	answer is ministerial correction date of answer 20/07/2018 answer text <p>A search of the Department’s Ministerial correspondence database has identified one item of correspondence received in 2017 about the availability of olanzapine and quetiapine. This figure represents correspondence received by the Department’s Ministerial correspondence unit only. We are not aware of any further representations.</p><p> </p><p>We do not hold any information on items prescribed but not dispensed.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/07/2018 09:42:16 answering member 4067 label Biography information for Steve Brine
	tabling member	207 label Biography information for Sir Vince Cable

938700

	registered interest
	date	11/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Olanzapine and Quetiapine
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what representations his Department has made to manufacturers of (a) olanzapine and (b) quetiapine on the supply of those drugs since 2017.
	tabling member constituency	Twickenham
	tabling member printed	Sir Vince Cable
	uin	162969
	answer	answer is ministerial correction date of answer 20/07/2018 answer text <p>Departmental officials are aware that there were some short term supply issues which affected the availability of olanzapine and quetiapine tablets in May/June 2017.</p><p> </p><p>A major generic supplier of olanzapine tablets experienced some short term manufacturing issues which consequently meant other suppliers experienced an increase in demand at short notice, which they could not readily meet. However, the manufacturing issues were resolved quickly and the overall supply of olanzapine tablets improved within a few weeks.</p><p> </p><p>In terms of quetiapine supply issues, this was caused by a major generic supplier, with large market shares of quetiapine tablets, discontinuing this product range without notifying the Department. This led to significant market disruption as other suppliers experienced a large increase in demand at short notice. However, suppliers were able to bring in additional supplies to cope with the extra demand and supplies improved by July 2017.</p><p> </p><p>During this period, Departmental officials were in regular contact with all United Kingdom licensed suppliers of both quetiapine and olanzapine and worked closely with them to discuss their supply position and to ensure sufficient suppliers remained available to meet UK requirements.</p><p> </p><p>We are not aware of any current supply issues affecting olanzapine and quetiapine and several suppliers have confirmed that supplies are readily available.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 162968 163503 question first answered 20/07/2018 09:38:48 answering member 4067 label Biography information for Steve Brine
	tabling member	207 label Biography information for Sir Vince Cable